Search company, investor...

Founded Year

2000

Stage

IPO | IPO

Total Raised

$34.11M

Date of IPO

11/5/2014

Market Cap

0.02B

Stock Price

2.96

About Nexstim

Nexstim develops, manufactures and markets Navigated Brain Stimulation devices for clinical use and scientific research

Headquarters Location

Elimäenkatu 9 B

Helsinki, FI-00510,

Finland

358 9 2727 1710

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Nexstim Patents

Nexstim has filed 23 patents.

The 3 most popular patent topics include:

  • Neuropsychology
  • Neuroscience
  • Electrotherapy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/27/2019

3/8/2022

Neurotechnology, Neurophysiology, Neuropsychology, Electrotherapy, Neuroscience

Grant

Application Date

5/27/2019

Grant Date

3/8/2022

Title

Related Topics

Neurotechnology, Neurophysiology, Neuropsychology, Electrotherapy, Neuroscience

Status

Grant

Latest Nexstim News

Nexstim Receives Order for NBS 5 System with NexSpeech®

Sep 26, 2023

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces having received an order for an NBS 5 system. The European end customer is new to Nexstim. Nexstim’s NBS (Navigated Brain Stimulation) System 5, in this case with the addition of the NexSpeech® module, is indicated for the non-invasive, presurgical mapping of motor and speech cortices of the brain. This specific system also includes therapeutic capabilities, allowing the system to be used for the treatment of major depression and chronic neuropathic pain as CE marked in Europe. Mikko Karvinen, CEO of Nexstim, comments: “Our solutions help neurosurgeons plan their most delicate surgeries. With our state-of-the-art nTMS (navigated transcranial magnetic stimulation) technology, neurosurgeons can get the most crucial information regarding the location of the tumor in the brain in relation to the brain’s vital functions and their connections. We at Nexstim are happy to welcome a new customer to our extensive community of neurosurgery customers.” Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain. Nexstim shares are listed on Nasdaq First North Growth Market Finland. For more information, please visit www.nexstim.com

Nexstim Frequently Asked Questions (FAQ)

  • When was Nexstim founded?

    Nexstim was founded in 2000.

  • Where is Nexstim's headquarters?

    Nexstim's headquarters is located at Elimäenkatu 9 B, Helsinki.

  • What is Nexstim's latest funding round?

    Nexstim's latest funding round is IPO.

  • How much did Nexstim raise?

    Nexstim raised a total of $34.11M.

  • Who are the investors of Nexstim?

    Investors of Nexstim include Sitra Ventures, HealthCap Venture Capital, Finnish Industry Investment, Ilmarinen Pension Insurance, Lundbeckfond Ventures and 6 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.